# Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018

> **NCT05228613** · PHASE1 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 175 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 protein subunit recombinant vaccine
- **BIOLOGICAL:** SARS-CoV-2 inactivated vaccine

## Key facts

- **NCT ID:** NCT05228613
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-16
- **Primary completion:** 2022-08-02
- **Final completion:** 2023-01-24
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2023-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05228613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05228613, "Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05228613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*